These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8201590)

  • 1. Novel Asp32-replacement tetrapeptide analogues as potent and selective CCK-A agonists.
    Elliott RL; Kopecka H; Tufano MD; Shue YK; Gauri AJ; Lin CW; Bianchi BR; Miller TR; Witte DG; Stashko MA
    J Med Chem; 1994 May; 37(11):1562-8. PubMed ID: 8201590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCK-A-selective tetrapeptides containing lys(N epsilon)-amide residues: favorable in vivo and in vitro effects of N-methylation at the aspartyl residue.
    Bennett MJ; Nikkel AL; Bianchi BR; Miller TR; Bednarz L; Witte DG; Stashko M; Wang SS; Gore PA; Asin KE
    J Med Chem; 1994 May; 37(11):1569-71. PubMed ID: 8201591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological activity of CCK heptapeptide analogues. Effects of conformational constraints and standard modifications on receptor subtype selectivity, functional activity in vitro, and appetite suppression in vivo.
    Holladay MW; Bennett MJ; Tufano MD; Lin CW; Asin KE; Witte DG; Miller TR; Bianchi BR; Nikkel AL; Bednarz L
    J Med Chem; 1992 Aug; 35(16):2919-28. PubMed ID: 1501220
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrapeptide CCK-A agonists: effect of backbone N-methylations on in vitro and in vivo CCK activity.
    Holladay MW; Kopecka H; Miller TR; Bednarz L; Nikkel AL; Bianchi BR; Witte DG; Shiosaki K; Lin CW; Asin KE
    J Med Chem; 1994 Mar; 37(5):630-5. PubMed ID: 8126703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrapeptide CCK agonists: structure-activity studies on modifications at the N-terminus.
    Elliott RL; Kopecka H; Bennett MJ; Shue YK; Craig R; Lin CW; Bianchi BR; Miller TR; Witte DG; Stashko MA
    J Med Chem; 1994 Jan; 37(2):309-13. PubMed ID: 8295219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of CCK-tetrapeptide analogues as potent and selective CCK-A receptor agonists.
    Shiosaki K; Lin CW; Kopecka H; Craig R; Wagenaar FL; Bianchi B; Miller T; Witte D; Nadzan AM
    J Med Chem; 1990 Nov; 33(11):2950-2. PubMed ID: 1700123
    [No Abstract]   [Full Text] [Related]  

  • 7. Structure-based design of new constrained cyclic agonists of the cholecystokinin CCK-B receptor.
    Blommaert AG; Dhôtel H; Ducos B; Durieux C; Goudreau N; Bado A; Garbay C; Roques BP
    J Med Chem; 1997 Feb; 40(5):647-58. PubMed ID: 9057851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Replacement of glycine with dicarbonyl and related moieties in analogues of the C-terminal pentapeptide of cholecystokinin: CCK(2) agonists displaying a novel binding mode.
    Bellier B; Million ME; DaNascimento S; Meudal H; Kellou S; Maigret B; Garbay C
    J Med Chem; 2000 Oct; 43(20):3614-23. PubMed ID: 11020275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of potent and selective CCK-A receptor agonists from Boc-CCK-4: tetrapeptides containing Lys(N epsilon)-amide residues.
    Shiosaki K; Lin CW; Kopecka H; Craig RA; Bianchi BR; Miller TR; Witte DG; Stashko M; Nadzan AM
    J Med Chem; 1992 May; 35(11):2007-14. PubMed ID: 1375964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analogs of CCK incorporating conformationally constrained replacements for Asp32.
    Tilley JW; Danho W; Madison V; Fry D; Swistok J; Makofske R; Michalewsky J; Schwartz A; Weatherford S; Triscari J
    J Med Chem; 1992 Oct; 35(22):4249-52. PubMed ID: 1433225
    [No Abstract]   [Full Text] [Related]  

  • 11. CCK-A receptor selective antagonists derived from the CCK-A receptor selective tetrapeptide agonist Boc-Trp-Lys(Tac)-Asp-MePhe-NH2 (A-71623).
    Sugg EE; Kimery MJ; Ding JM; Kenakin DC; Miller LJ; Queen KL; Rimele TJ
    J Med Chem; 1995 Jan; 38(1):207-11. PubMed ID: 7837233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors.
    Lin CW; Shiosaki K; Miller TR; Witte DG; Bianchi BR; Wolfram CA; Kopecka H; Craig R; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1991 Mar; 39(3):346-51. PubMed ID: 1706470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and binding affinities of cyclic and related linear analogues of CCK8 selective for central receptors.
    Charpentier B; Dor A; Roy P; England P; Pham H; Durieux C; Roques BP
    J Med Chem; 1989 Jun; 32(6):1184-90. PubMed ID: 2724293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of cholecystokinin analogs in which the Asp-Phe-NH2 moiety has been replaced by a 3-amino-7-phenylheptanoic acid or a 3-amino-6-(phenyloxy)hexanoic acid.
    Amblard M; Rodriguez M; Lignon MF; Galas MC; Bernad N; Artis-Noël AM; Hauad L; Laur J; Califano JC; Aumelas A
    J Med Chem; 1993 Oct; 36(20):3021-8. PubMed ID: 7692048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CCK-B agonist or antagonist activities of structurally hindered and peptidase-resistant Boc-CCK4 derivatives.
    Corringer PJ; Weng JH; Ducos B; Durieux C; Boudeau P; Bohme A; Roques BP
    J Med Chem; 1993 Jan; 36(1):166-72. PubMed ID: 8421283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CCK peptides with combined features of hexa- and tetrapeptide CCK-A agonists.
    Pierson ME; Comstock JM; Simmons RD; Julien R; Kaiser F; Rosamond JD
    J Med Chem; 2000 Jun; 43(12):2350-5. PubMed ID: 10882360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conformationally readdressed CCK-B/delta-opioid peptide ligands.
    Nikiforovich GV; Kolodziej SA; Nock B; Bernad N; Martinez J; Marshall GR
    Biopolymers; 1995 Oct; 36(4):439-52. PubMed ID: 7578939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of N- and C-terminal substituents on the CCK-B agonist-antagonist pharmacological profile of Boc-Trp-Phg-Asp-Nal-NH2 derivatives.
    Weng JH; Blommaert AG; Moizo L; Bado A; Ducos B; Böhme A; Garbay C; Roques BP
    Bioorg Med Chem; 1996 Apr; 4(4):563-73. PubMed ID: 8735845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of topographical constraints in receptor mapping: investigation of the topographical requirements of the tryptophan 30 residue for receptor binding of Asp-Tyr-D-Phe-Gly-Trp-(N-Me)Nle-Asp-Phe-NH2 (SNF 9007), a cholecystokinin (26-33) analogue that binds to both CCK-B and delta-opioid receptors.
    Boteju LW; Nikiforovich GV; Haskell-Luevano C; Fang SN; Zalewska T; Stropova D; Yamamura HI; Hruby VJ
    J Med Chem; 1996 Sep; 39(20):4120-4. PubMed ID: 8831778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological activities of pseudopeptide analogues of the C-terminal heptapeptide of cholecystokinin. On the importance of the peptide bonds.
    Rodriguez M; Lignon MF; Galas MC; Fulcrand P; Mendre C; Aumelas A; Laur J; Martinez J
    J Med Chem; 1987 Aug; 30(8):1366-73. PubMed ID: 2441054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.